8-K: ProMIS Neurosciences Reports Q3 2025, Advances AD Trial

ProMIS Neurosciences announced its third quarter 2025 financial results and significant progress in its lead Alzheimer's disease clinical trial, PMN310.

Summary

• ProMIS Neurosciences reported financial results for the third quarter ended September 30, 2025, alongside key corporate and clinical highlights.
• The company's lead candidate, PMN310, for Alzheimer's disease (AD), is over 85% enrolled in its Phase 1b trial, with Cohorts 1 and 2 fully enrolled and Cohort 3 well underway.
• Complete enrollment for the PMN310 Phase 1b trial is expected before the end of 2025.
• PMN310 continues to demonstrate a favorable safety profile, with low incidence of amyloid-related imaging abnormalities (ARIA) and serious adverse events (SAEs).
• The independent Data and Safety Monitoring Board (DSMB) unanimously recommended proceeding to the third and final dose escalation cohort for PMN310.
• Cash and cash equivalents increased to $15.4 million as of September 30, 2025, from $13.3 million at December 31, 2024, primarily due to a $21.6 million capital raise in July 2025.
• Research and development expenses significantly increased to $9.8 million for Q3 2025, up from $2.6 million for Q3 2024, driven by the PRECISE-AD Phase 1b clinical trial.
• Loss from operations for Q3 2025 was $11.8 million, compared to $4.4 million for Q3 2024, mainly due to increased R&D expenditures.
• Net loss for Q3 2025 was $11.6 million, compared to a net income of $9.3 million for Q3 2024 (the prior year's income was influenced by a large change in fair value of financial instruments).

Sentiment

Score: 7

Explanation: Despite increased financial losses due to higher R&D expenses, the sentiment is positive due to significant clinical trial progress (over 85% enrollment, favorable safety, DSMB approval), successful capital raise, and pipeline advancement, which are critical milestones for a clinical-stage biotech.

Positives

• PMN310 Phase 1b trial for Alzheimer's disease is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 well into progress.
• Complete enrollment for the PMN310 Phase 1b trial is anticipated before the end of 2025.
• PMN310 maintains a favorable safety profile, showing low incidence of amyloid-related imaging abnormalities (ARIA) and serious adverse events (SAEs).
• The independent Data and Safety Monitoring Board (DSMB) unanimously approved advancing PMN310 to the third and final dose escalation cohort.
• PMN310 was granted Fast Track Designation by the U.S. Food and Drug Administration in July 2025.
• The company successfully raised approximately $21.6 million in aggregate gross proceeds from a registered direct offering, private placements, and discounted warrant exercises in July 2025, significantly boosting cash reserves.
• Pipeline programs PMN267 (ALS) and PMN442 (PD/MSA) are ready to progress to IND-enabling studies, indicating broader platform utility.
• Slanix Paul Alex, President and Portfolio Manager for Ally Bridge Group's Public Equity strategy, joined the Board, enhancing investment community awareness.

Negatives

• Research and development expenses increased significantly to $9.8 million for the third quarter ended September 30, 2025, from $2.6 million for the same period in 2024.
• Loss from operations increased to $11.8 million for Q3 2025, compared to an operating loss of $4.4 million for Q3 2024.
• Net loss for Q3 2025 was $11.6 million, a significant decrease from the net income of $9.3 million reported in Q3 2024 (though the prior year's income was heavily influenced by non-operating items).

Risks

• Preclinical results or early clinical results may not be indicative of future results.
• The company's ability to fund its operations and continue as a going concern.
• The accumulated deficit and the expectation for continued losses and future financial results.
• Other factors discussed throughout the Risk Factors section of the company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2024, and in its subsequent filings.

Future Outlook

The company anticipates completing enrollment for its PRECISE-AD Phase 1b trial for PMN310 before the end of 2025. Six-month interim data from this trial is expected in Q2 2026, with final 12-month top-line results projected for Q4 2026. Additionally, pipeline programs PMN267 for ALS and PMN442 for PD/MSA are ready to advance to IND-enabling studies, indicating future development activities.

Management Comments

• "2025 has been a year of intense focus and successful execution for the team at ProMIS."
• "We have reinforced the Company's strong foundation both strategically and clinically by bringing in additional capital to support our stated goals and adding Slanix Paul Alex, Pharm.D., President and Portfolio Manager for Ally Bridge Group's Public Equity strategy to our Board."
• "Collectively, this amplifies awareness amongst the investment community as we approach the nearing completed enrollment of our PRECISE-AD trial evaluating our first clinical candidate, PMN310, which was designed using our proprietary EpiSelectTM computational drug discovery engine."
• "All of this is ultimately preparing the Company for its multiple key anticipated inflection points in 2026 and endeavoring to deliver on its promise of developing next-generation therapies for AD and for other neurogenerative disorders."

Industry Context

ProMIS Neurosciences operates in the highly competitive and high-risk, high-reward biotechnology sector, specifically targeting neurodegenerative diseases like Alzheimer's, ALS, and Parkinson's. The development of antibody therapeutics for these conditions is a major focus within the industry, with significant unmet medical needs. The company's proprietary EpiSelectTM platform aims to differentiate its candidates by selectively targeting toxic misfolded proteins, potentially offering advantages over existing or developing therapies that may have off-target effects or higher risks of side effects like ARIA.

Comparison to Industry Standards

• PMN310 is designed to selectively target toxic amyloid-beta oligomers (AO) while avoiding plaque, which the company believes could potentially reduce or eliminate amyloid-related imaging abnormalities (ARIA) liability, a common side effect with other amyloid-directed antibody therapeutics.
• The company suggests that PMN310's design may offer an improved efficacy profile over other amyloid-directed antibody therapeutics by not being limited by off-target binding or side effects, though specific comparative data to named competitors or projects are not provided in this filing.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future value creation from successful clinical development, but also dilution from recent capital raise and continued operational losses.
• Patients: Continued progress in developing potential next-generation therapies for Alzheimer's, ALS, and Parkinson's diseases.
• Employees: Continued employment and focus on executing clinical and strategic goals.
• Investment Community: Increased awareness and potential interest due to clinical milestones and new board member.

Next Steps

• Complete enrollment for the PMN310 Phase 1b trial before the end of 2025.
• Report 6-month interim data for the PMN310 Phase 1b trial in Q2 2026.
• Report final 12-month top-line results for the PMN310 Phase 1b trial in Q4 2026.
• Progress PMN267 (ALS) and PMN442 (PD/MSA) pipeline programs to IND-enabling studies.

Key Dates

Keywords

Alzheimer's disease, Neurodegenerative diseases, PMN310, Clinical trial, Biotechnology, Antibody therapeutics, Amyloid-beta oligomers, Fast Track Designation, ALS, Parkinson's disease, EpiSelect, Q3 2025 financial results